These developments represent a new era in cancer therapy. It offers hope for better treatment outcomes when these new drugs are combined with other anti-cancer medicines.The first immuno-oncology drugs have now been approved by the competent authorities for use in healthcare.
– Have they been treated differently in terms of documentation requirements, investigation time, scope of indication and follow-up studies?
– What are the opportunities and risks when new medicines reach patients in need?
– What are the most promising developments in immuno-oncology?
– How will the new medicines be best used?
– What is the place of chemotherapy in the new environment?
– How should the cost level be managed to allow for equal use across the healthcare system?
PROGRAM AND PARTICIPANTS
Introduction
Professor Kjell Strandberg, former DG Medical Products Agency
What is immuno-oncology?
Magnus Jäderberg CMO Targovax, London
The new cancer drugs in a clinical perspective
Professor Peter Nygren, Oncology Clinic, Uppsala University Hospital, Uppsala, Sweden
Faster approval of new cancer drugs?
Tomas Salmonson, Chair of the EU’s Committee for Medicinal Products for Human Use (CHMP) and Bertil Jonsson Chair of CHMP’s Oncology Working Party, European Medicines Agency (EMA) London
Price, value and payment
Professor Bengt Jönsson, Stockholm School of Economics
Equal access for patients to the new medicines?
Mats Eriksson, Chairman of the Regional Board, Region Halland
Panel discussion
Moderator, Björn Odlander, Managing Partner HealthCap
Welcome to the website
Inger Andersson, Chair of IVA’s Department of Biotechnology
